Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091661 | 0.85 | ALDH1A1 (0.64) | KDM4EALDH1A1KMT2ASTAT3TSHR | |
| SCHEMBL6090918 | 0.85 | CREBBP (0.58) | KDM4EALDH1A1MAPTPTGDR2TBXAS1 | |
| SCHEMBL2546174 | 0.76 | KMT2A (0.62) | KDM4EALDH1A1KMT2ASTAT3TSHR | |
| SCHEMBL14631628 | 0.74 | KMT2A (0.60) | KDM4EALDH1A1KMT2ASTAT3TSHR | |
| SCHEMBL3307798 | 0.74 | KMT2A (0.74) | KDM4EALDH1A1KMT2ASTAT3TSHR | |
| SCHEMBL1520240 | 0.74 | TBXAS1 (0.64) | KDM4EALDH1A1KMT2ASTAT3TSHR | |
| SCHEMBL3307790 | 0.74 | KMT2A (0.60) | KDM4EALDH1A1KMT2ASTAT3TSHR | |
| SCHEMBL12874520 | 0.73 | KMT2A (0.66) | KDM4EALDH1A1KMT2ASTAT3TSHR | |
| SCHEMBL18180209 | 0.73 | CDC25A (0.63) | KDM4EALDH1A1KMT2ASTAT3TBXAS1 | |
| SCHEMBL12479832 | 0.72 | KMT2A (0.73) | KDM4EALDH1A1KMT2ASTAT3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | disclosed |
| CN-1742007-A | Indole-derivative modulators of steroid hormone nuclear receptors | LILLY CO ELI (US) | 2006-03-01 | — | — | CN | disclosed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | NR3C2, NR5A1, MC2R | KDM4E 3154/4885ALDH1A1 1544/4885KMT2A 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.